Company intelligence / Profile preview

Alchemia Oncology

South Melbourne, Victoria, Australiamarketscreener.com ↗

Ownership: Private
Employees: ~4900
Development stage: Other

Overview

The company completed recruitment of 390 patients for a pivotal Phase III clinical trial of HA-Irinotecan in metastatic colorectal cancer. Earlier Phase II studies showed statistically significant improvement in progression-free survival compared to irinotecan alone (20.8 vs 9.6 weeks, p=0.017). Early responses in lung cancer trials were described as "extremely encouraging."[6][9]

Therapeutic areas: Oncology
Modalities: Small moleculeshyaluronic acid-based drug delivery
Industry: Biotech

Partnerships

Dr. Reddy's Laboratories (for Fondaparinux)

Beyond the preview

Go deeper on Alchemia Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alchemia Oncology.

Explore the full profile